



# **SUVN-D4010**

## **5-HT<sub>4</sub> Partial Agonist**

**Dual Mechanism of Action (Disease Modifying and Symptomatic Treatment Potential for AD)**

**Phase 1 Completed in USA; Ready for Phase 2 POC**



# SUVN-D4010: Key Features




- Selective serotonin-4 receptor (5-HT<sub>4</sub>) partial agonist
- Orally bioavailable with good brain penetration
- Good correlation between affinity, free fraction and efficacy
- Clean in hERG, phospholipidosis and AMES assays
- No QT/QTc prolongation in dog telemetry study
- Robust efficacy in animal models
- Potentiates the efficacy of cholinesterase inhibitors in animal models
- Disease modifying effects in animal models
- Translatable biomarker available for POC study
- Good margin of safety in preclinical studies
- No genotoxicity and teratogenic potential
- Well protected intellectual property in all major markets
- Safe and well tolerated in healthy adult subjects (Phase-1 study)
- Excellent human pharmacokinetics suitable for once a day treatment
- Projected human efficacy concentrations achieved in Phase-1 study
- No effect of food, gender and age on human pharmacokinetics


# SUVN-D4010: Key Pharmacology Results




## Target Engagement in Rats



## Object Recognition Task in Rats



## Modulation of sAPP $\alpha$ Levels



**Disease Modifying and Symptomatic Treatment Potential for Alzheimer's Disease**

# SUVN-D4010: Clinical Studies Summary and Current Status



- Well tolerated in humans with dose dependent pharmacokinetics
- Suitable for once a day oral dosing
- Projected human efficacy concentrations achieved at low doses in Phase 1 study

**Current status: Phase 1 Completed in USA; Ready for Phase 2 POC**



# Contacts:

**Venkat Jasti**

**Chairman & CEO**

**E-mail: [jasti@suven.com](mailto:jasti@suven.com)**

**Ramakrishna Nirogi**

**Vice President, Discovery Research**

**E-mail: [nvsrk@suven.com](mailto:nvsrk@suven.com)**